En résumé, l'analyste de Wells Fargo a réitéré sa confiance dans la position d'Eli Lilly sur le marché, soutenue par les avancées de la société dans les traitements de perte de poids et leur ...
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
(Reuters) -Eli Lilly raised its full-year profit and revenue forecast on Tuesday after demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro surged, sending its shares up ...
ELI LILLY AND COMPANY : China International Capital maintient sa recommandation à l'achat 08/05 ZM ELI LILLY AND COMPANY : JPMorgan Chase toujours neutre sur le dossier 01/05 ZM ELI LILLY AND ...
Mardi, Argus a maintenu une note d'achat sur Eli Lilly & Co. (NYSE: LLY) et a relevé son objectif de cours à 840 dollars, contre 770 dollars auparavant. Cette révision reflète le succès des ventes de ...
Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and a steady ramp up of production of its weight-loss treatment Zepbound and related diabetes drug Mounjaro, ...